170900.Ks
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.52, suggesting it can cover its short-term obligations but with limited excess capacity. The company's price-to-book ratio is 0.62, which is below 1, indicating that the market values the company at a discount to its book value. This may reflect concerns about the company's profitability or future growth prospects.
Profitability metrics show a challenging performance, with a negative return on equity (ROE) of -4.45% and a negative return on assets (ROA) of -2.02%. These figures are below the typical thresholds for industry leaders and suggest that the company is not generating returns that meet the cost of capital. The operating margin is also negative, with an operating loss of 17.4 billion KRW, which is a significant concern for investors. The company's net income is also negative, at -28.6 billion KRW, further highlighting its financial distress.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region. The absence of detailed segment or geographic breakdowns in the available data limits the ability to assess the company's exposure to different markets.
The company's growth trajectory is mixed. While it reported a revenue of 808.78 billion KRW, the operating and net losses suggest that the company is not currently generating sustainable earnings. Analysts have provided a mean price target of 61,244.90 KRW, which is significantly higher than the current market price of 41,500 KRW, indicating some optimism about the company's future performance. However, the company's free cash flow is negative at -48.17 billion KRW, and its capital expenditures are also negative, suggesting that the company is not investing in growth and may be facing liquidity constraints.
The company's risk profile is elevated, with a liquidity risk due to negative net cash after subtracting total debt. The risk assessment also highlights the potential for dilution, although the current level is assessed as low. The company's negative operating and net income, combined with its high debt load, increases the risk of financial distress and the potential need for further equity or debt financing, which could dilute existing shareholders.
Recent events, as reflected in the financial data, indicate a period of financial stress for the company. The negative operating and net income, along with the negative free cash flow, suggest that the company is not currently generating sufficient cash to sustain operations or fund growth. The company's capital expenditures are also negative, indicating a lack of investment in new projects or expansion. These factors, combined with the high debt-to-equity ratio, suggest that the company may need to take corrective actions to improve its financial position.
- The company is currently unprofitable, with negative operating and net income, indicating a need for strategic and operational improvements.
- The company's liquidity position is moderate, with a current ratio of 1.52, but it faces a liquidity risk due to negative net cash after subtracting total debt.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.84, which may increase financial risk.
- Analysts have a generally positive outlook, with a mean price target significantly higher than the current market price, suggesting potential for recovery.
- The company's lack of geographic and segment diversification increases its exposure to market-specific risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 170900.KS Market data — financials · 2026-05-26
- Dong-A ST Co Ltd Market data — analyst estimates · 2026-05-26